{"id":28113,"date":"2021-08-20T15:31:19","date_gmt":"2021-08-20T19:31:19","guid":{"rendered":"https:\/\/nephcure.org\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\/"},"modified":"2024-05-01T16:35:50","modified_gmt":"2024-05-01T20:35:50","slug":"resultados-provisionales-alentadores-del-ensayo-traveres-protect-para-pacientes-igan","status":"publish","type":"post","link":"https:\/\/nephcure.org\/es\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\/","title":{"rendered":"Resultados provisionales alentadores del ensayo PROTECT de Travere para pacientes con NIgA"},"content":{"rendered":"<p>Se han anunciado los resultados provisionales.<span class=\"Apple-converted-space\">\u00a0 <\/span>del estudio PROTECT de Travere Therapeutic y, aunque preliminares, los datos parecen prometedores para los pacientes con nefropat\u00eda por IgA (NIgA).<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>El ensayo de fase 3 en curso de Travere est\u00e1 estudiando el f\u00e1rmaco sparsentan en pacientes con NIgA.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>En promedio, los pacientes que recibieron sparsentan experimentaron una reducci\u00f3n de la proteinuria de casi 50% despu\u00e9s de 36 semanas. Eso es aproximadamente tres veces m\u00e1s que el control activo. El derrame activo de prote\u00ednas (proteinuria) provoca da\u00f1o renal. La prioridad para todo paciente debe ser suspender o reducir las prote\u00ednas en la orina.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>Hasta la fecha, los participantes en el estudio han tolerado bien el sparsesentan. A diferencia de los esteroides y otros medicamentos no aprobados com\u00fanmente recetados para enfermedades renales progresivas como la NIgA, el sparsentan no es un inmunosupresor.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>Esta noticia llega apenas unos meses despu\u00e9s de que los datos provisionales del estudio DUPLEX de fase 3 de Travere que eval\u00faa el sparsentan en la FSGS tambi\u00e9n alcanzaran su criterio de valoraci\u00f3n provisional de proteinuria.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>Los estudios PROTECT y DUPLEX son algunos de los estudios m\u00e1s grandes hasta la fecha para pacientes con NIgA y GEFS, respectivamente, que han alcanzado este nivel de datos de ensayo. Es posible que estos resultados conduzcan en \u00faltima instancia a una posible aprobaci\u00f3n del sparsentan.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>Para leer m\u00e1s sobre los resultados provisionales de Travere del estudio PROTECT en IgAN, haga clic en <a href=\"https:\/\/ir.travere.com\/news-releases\/news-release-details\/travere-therapeutics-announces-positive-topline-interim-results\">aqu\u00ed<\/a>.<\/p>\n<p>\u00bfQuiere obtener m\u00e1s informaci\u00f3n sobre esta investigaci\u00f3n y lo que podr\u00eda significar para los pacientes con NIgA y otras enfermedades renales progresivas que derraman prote\u00ednas? \u00danase a la enfermera Kristen de NephCure en <a href=\"https:\/\/www.facebook.com\/nephcure\">facebook en vivo<\/a> el 25 de agosto<sup>th<\/sup> donde analiza esta noticia con m\u00e1s detalle: desglosa los resultados del estudio, qui\u00e9nes podr\u00edan verse afectados por esta investigaci\u00f3n y cu\u00e1l podr\u00eda ser el cronograma para ver nuevos tratamientos para la NIgA, la FSGS y otras enfermedades renales raras que derraman prote\u00ednas.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Se han anunciado resultados provisionales del estudio PROTECT de Travere Therapeutic y, aunque preliminares, los datos parecen prometedores para los pacientes con nefropat\u00eda por IgA (NIgA). El ensayo de fase 3 en curso de Travere est\u00e1 estudiando el... <a title=\"Resultados provisionales alentadores del ensayo PROTECT de Travere para pacientes con NIgA\" class=\"read-more\" href=\"https:\/\/nephcure.org\/es\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\/\" aria-label=\"Leer m\u00e1s sobre Resultados provisionales alentadores del ensayo PROTECT de Travere para pacientes con NIgA\">Leer m\u00e1s<\/a><\/p>","protected":false},"author":222,"featured_media":28114,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[354],"tags":[],"disease-category":[],"resource-type":[260],"treatment-option":[],"hf_cat_post":[],"class_list":["post-28113","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent-news","resource-type-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Encouraging interim results from Travere\u2019s PROTECT trial for IgAN patients - NephCure<\/title>\n<meta name=\"description\" content=\"Interim results have been announced\u00a0 from Travere Therapeutic&#039;s PROTECT study, and although preliminary, the data look promising for IgA Nephropathy - Read more about Encouraging interim results from Travere\u2019s PROTECT trial for IgAN patients on NephCure.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nephcure.org\/es\/resultados-provisionales-alentadores-del-ensayo-traveres-protect-para-pacientes-igan\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Encouraging interim results from Travere\u2019s PROTECT trial for IgAN patients\" \/>\n<meta property=\"og:description\" content=\"Interim results have been announced\u00a0 from Travere Therapeutic&#039;s PROTECT study, and although preliminary, the data look promising for IgA Nephropathy - Read more about Encouraging interim results from Travere\u2019s PROTECT trial for IgAN patients on NephCure.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nephcure.org\/es\/resultados-provisionales-alentadores-del-ensayo-traveres-protect-para-pacientes-igan\/\" \/>\n<meta property=\"og:site_name\" content=\"NephCure\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/nephcure\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-20T19:31:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-01T20:35:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/travere_transition.png\" \/>\n\t<meta property=\"og:image:width\" content=\"689\" \/>\n\t<meta property=\"og:image:height\" content=\"148\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Lauren Eva\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@nephcure\" \/>\n<meta name=\"twitter:site\" content=\"@nephcure\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lauren Eva\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\\\/\"},\"author\":{\"name\":\"Lauren Eva\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/#\\\/schema\\\/person\\\/434bf0351b94952973f03e725afea9b7\"},\"headline\":\"Encouraging interim results from Travere\u2019s PROTECT trial for IgAN patients\",\"datePublished\":\"2021-08-20T19:31:19+00:00\",\"dateModified\":\"2024-05-01T20:35:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\\\/\"},\"wordCount\":280,\"publisher\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/travere_transition.png\",\"articleSection\":[\"Recent News\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\\\/\",\"url\":\"https:\\\/\\\/nephcure.org\\\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\\\/\",\"name\":\"Encouraging interim results from Travere\u2019s PROTECT trial for IgAN patients - NephCure\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/travere_transition.png\",\"datePublished\":\"2021-08-20T19:31:19+00:00\",\"dateModified\":\"2024-05-01T20:35:50+00:00\",\"description\":\"Interim results have been announced\u00a0 from Travere Therapeutic's PROTECT study, and although preliminary, the data look promising for IgA Nephropathy - Read more about Encouraging interim results from Travere\u2019s PROTECT trial for IgAN patients on NephCure.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nephcure.org\\\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/travere_transition.png\",\"contentUrl\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/travere_transition.png\",\"width\":689,\"height\":148},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nephcure.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Encouraging interim results from Travere\u2019s PROTECT trial for IgAN patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/#website\",\"url\":\"https:\\\/\\\/nephcure.org\\\/\",\"name\":\"NephCure\",\"description\":\"For Rare Kidney Disease\",\"publisher\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nephcure.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/#organization\",\"name\":\"NephCure\",\"url\":\"https:\\\/\\\/nephcure.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/cropped-NephCure-favicon-512x512-1.png\",\"contentUrl\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/cropped-NephCure-favicon-512x512-1.png\",\"width\":512,\"height\":512,\"caption\":\"NephCure\"},\"image\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/nephcure\\\/\",\"https:\\\/\\\/x.com\\\/nephcure\",\"https:\\\/\\\/www.instagram.com\\\/nephcure\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nephcure\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/Nephcure\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/#\\\/schema\\\/person\\\/434bf0351b94952973f03e725afea9b7\",\"name\":\"Lauren Eva\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g\",\"caption\":\"Lauren Eva\"},\"sameAs\":[\"https:\\\/\\\/nephcure.org\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Resultados provisionales alentadores del ensayo PROTECT de Travere para pacientes con NIgA - NephCure","description":"Se han anunciado los resultados provisionales del estudio PROTECT de Travere Therapeutic y, aunque preliminares, los datos parecen prometedores para la nefropat\u00eda por IgA. Lea m\u00e1s sobre Resultados provisionales alentadores del ensayo PROTECT de Travere para pacientes con NIgA tratados con NephCure.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nephcure.org\/es\/resultados-provisionales-alentadores-del-ensayo-traveres-protect-para-pacientes-igan\/","og_locale":"es_MX","og_type":"article","og_title":"Encouraging interim results from Travere\u2019s PROTECT trial for IgAN patients","og_description":"Interim results have been announced\u00a0 from Travere Therapeutic's PROTECT study, and although preliminary, the data look promising for IgA Nephropathy - Read more about Encouraging interim results from Travere\u2019s PROTECT trial for IgAN patients on NephCure.","og_url":"https:\/\/nephcure.org\/es\/resultados-provisionales-alentadores-del-ensayo-traveres-protect-para-pacientes-igan\/","og_site_name":"NephCure","article_publisher":"https:\/\/www.facebook.com\/nephcure\/","article_published_time":"2021-08-20T19:31:19+00:00","article_modified_time":"2024-05-01T20:35:50+00:00","og_image":[{"width":689,"height":148,"url":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/travere_transition.png","type":"image\/png"}],"author":"Lauren Eva","twitter_card":"summary_large_image","twitter_creator":"@nephcure","twitter_site":"@nephcure","twitter_misc":{"Escrito por":"Lauren Eva","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nephcure.org\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\/#article","isPartOf":{"@id":"https:\/\/nephcure.org\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\/"},"author":{"name":"Lauren Eva","@id":"https:\/\/nephcure.org\/#\/schema\/person\/434bf0351b94952973f03e725afea9b7"},"headline":"Encouraging interim results from Travere\u2019s PROTECT trial for IgAN patients","datePublished":"2021-08-20T19:31:19+00:00","dateModified":"2024-05-01T20:35:50+00:00","mainEntityOfPage":{"@id":"https:\/\/nephcure.org\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\/"},"wordCount":280,"publisher":{"@id":"https:\/\/nephcure.org\/#organization"},"image":{"@id":"https:\/\/nephcure.org\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/travere_transition.png","articleSection":["Recent News"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nephcure.org\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\/","url":"https:\/\/nephcure.org\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\/","name":"Resultados provisionales alentadores del ensayo PROTECT de Travere para pacientes con NIgA - NephCure","isPartOf":{"@id":"https:\/\/nephcure.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nephcure.org\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\/#primaryimage"},"image":{"@id":"https:\/\/nephcure.org\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/travere_transition.png","datePublished":"2021-08-20T19:31:19+00:00","dateModified":"2024-05-01T20:35:50+00:00","description":"Se han anunciado los resultados provisionales del estudio PROTECT de Travere Therapeutic y, aunque preliminares, los datos parecen prometedores para la nefropat\u00eda por IgA. Lea m\u00e1s sobre Resultados provisionales alentadores del ensayo PROTECT de Travere para pacientes con NIgA tratados con NephCure.","breadcrumb":{"@id":"https:\/\/nephcure.org\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nephcure.org\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nephcure.org\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\/#primaryimage","url":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/travere_transition.png","contentUrl":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/travere_transition.png","width":689,"height":148},{"@type":"BreadcrumbList","@id":"https:\/\/nephcure.org\/encouraging-interim-results-from-traveres-protect-trial-for-igan-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nephcure.org\/"},{"@type":"ListItem","position":2,"name":"Encouraging interim results from Travere\u2019s PROTECT trial for IgAN patients"}]},{"@type":"WebSite","@id":"https:\/\/nephcure.org\/#website","url":"https:\/\/nephcure.org\/","name":"NephCure","description":"Para enfermedades renales raras","publisher":{"@id":"https:\/\/nephcure.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nephcure.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nephcure.org\/#organization","name":"NephCure","url":"https:\/\/nephcure.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nephcure.org\/#\/schema\/logo\/image\/","url":"https:\/\/nephcure.org\/wp-content\/uploads\/2023\/03\/cropped-NephCure-favicon-512x512-1.png","contentUrl":"https:\/\/nephcure.org\/wp-content\/uploads\/2023\/03\/cropped-NephCure-favicon-512x512-1.png","width":512,"height":512,"caption":"NephCure"},"image":{"@id":"https:\/\/nephcure.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/nephcure\/","https:\/\/x.com\/nephcure","https:\/\/www.instagram.com\/nephcure\/","https:\/\/www.linkedin.com\/company\/nephcure\/","https:\/\/www.youtube.com\/user\/Nephcure"]},{"@type":"Person","@id":"https:\/\/nephcure.org\/#\/schema\/person\/434bf0351b94952973f03e725afea9b7","name":"loren eva","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g","caption":"Lauren Eva"},"sameAs":["https:\/\/nephcure.org"]}]}},"_links":{"self":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/posts\/28113","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/users\/222"}],"replies":[{"embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/comments?post=28113"}],"version-history":[{"count":0,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/posts\/28113\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/media\/28114"}],"wp:attachment":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/media?parent=28113"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/categories?post=28113"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/tags?post=28113"},{"taxonomy":"disease-category","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/disease-category?post=28113"},{"taxonomy":"resource-type","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/resource-type?post=28113"},{"taxonomy":"treatment-option","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/treatment-option?post=28113"},{"taxonomy":"hf_cat_post","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/hf_cat_post?post=28113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}